Arcellx

company

About

Arcellx is a clinical-stage biotechnology company that provides patients with immune cell therapies.

Details

Last Funding Type
Post-IPO Equity
Last Funding Money Raised
$100M
Industries
Biopharma,Biotechnology,Health Care,Life Science,Pharmaceutical
Founded date
Jan 1, 2015
Number Of Employee
51 - 100
Operating Status
Active
Stock Symbol
nasdaq:ACLX
Legal Name
Arcellx, Inc.

Arcellx is a clinical-stage biotechnology company reimagining cell therapy by engineering innovative immunotherapies for patients with cancer and other incurable diseases. Arcellx believes that cell therapies are one of the forward pillars of medicine and Arcellx’s mission is to advance humanity by developing cell therapies that are safer, more effective, and more broadly accessible. Arcellx’s lead product candidate, CART-ddBCMA, is being developed for the treatment of relapsed or refractory multiple myeloma (r/r MM) in an ongoing Phase 1 study. CART-ddBCMA has been granted Fast Track, Orphan Drug, and Regenerative Medicine Advanced Therapy designations by the U.S. Food and Drug Administration.

Arcellx is also advancing its dosable and controllable CAR-T therapy, ARC-SparX, into the clinic through two programs: ACLX-001 in r/r MM and ACLX-002 in relapsed or refractory acute myeloid leukemia.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
7
$430.99M
Arcellx has raised a total of $430.99M in funding over 2 rounds. Their latest funding was raised on Dec 9, 2022 from a Post-IPO Equity round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Dec 9, 2022 Post-IPO Equity $100M 1 Kite Pharma Detail
Jun 15, 2022 Post-IPO Equity $112M Detail
Mar 10, 2022 Post-IPO Equity $9.99M Detail
Feb 4, 2022 IPO $124M Detail
Apr 13, 2021 Series C 7 CAM Capital Detail

Investors

Number of Lead Investors
Number of Investors
4
19
Arcellx is funded by 19 investors. Kite Pharma and CAM Capital are the most recent investors.
Investor Name Lead Investor Funding Round
Kite Pharma Yes Post-IPO Equity
CAM Capital Yes Series C
Aju IB Investment Yes Series B
Quan Capital Yes Series B
Adage Capital Management Series C
Asymmetry Ventures Series C
CaaS Capital Management Series C
Cambrian Biopharma Series C
Clough Capital Partners Series C
LG Technology Ventures Series C

Employee Profiles

Number of Employee Profiles
9
Arcellx has 9 current employee profiles, including Board observer Sha Wang
Board observer
Executive
Board member
Executive
Executive